- Industry
- Biotech: drug discovery tools and organoids
- Stage
- University spin-out, from concept to product
- Elad’s role
- Co-founder and CTO
The client and the situation
Navigate Precision Biology, a University of Dundee spin-out.
Drug research has a very high failure rate. In a September 2024 talk in Edinburgh, Elad asked whether organoids, 3D tissue models grown in the lab, could be part of the solution and reduce the time, cost and waste involved.
For that, organoids have to be produced at the scale screening needs and in formats that model human disease. Navigate Precision Biology, a University of Dundee spin-out, set out to do this with the NaviPlate.
The problems
- An academic design needed protection and a route to customers before it could be a product.
- Screening customers needed a plate that fits automated, high-throughput work and many different readouts.
The journey
- Spin-outElad co-founded Navigate Precision Biology and serves as its CTO.
- IPThe NaviPlate is protected by registered design rights in Great Britain and the EU, with the US listed as pending.
- CustomersThe platform went through customer discovery, then commercial validation.
- ModelsHuman kidney disease models first, then miniaturized heart, lung and bone organoids.
- 2024Presented at ELRIG Drug Discovery 2024 as ready for high-throughput screening.
- MarketThe plates are offered to academic and non-profit institutions through the University of Dundee, with commercial access under research collaboration agreements.
The solution: technology and approach
- NaviPlate: an SBS-format 384-well organoid plate with one microcavity per well, flexible across readouts
- 384 identical organoids per plate in an automation-friendly format
- Seeding that needs very few stem cells
- Fluorescence-intensity live/dead assays on a BMG LABTECH PHERAstar FSX plate reader, down to about 500 cells per well
- Kidney and lung organoids for fibrosis, heart organoids for calcium-flux oscillations, bone microtissues for mineralization, and cancer microtissues
What they got
- The platform has been demonstrated in several disease areas and readouts, including models of osteoporosis and of chronic kidney, heart and lung disease.
- The NaviPlate is available to academic and non-profit institutions, with commercial access under research collaboration agreements.
- Elad reports running assays in the plate that had never been done before in microplates.
Sounds like your situation?
- You have a strong scientific platform and need to prove the market wants it.
- You are moving from a university lab to a spin-out.
- Your product has to fit how pharma and biotech customers already run their work.
Related services and use cases
- Your investor questions need technical evidence
- Make the next R&D milestone measurable
- Is your scientific prototype reproducible?
Sources
- Elad Katz’s profile on CTO Grand Rounds
- NaviPlate 384-well organoid plates - MRC PPU Reagents and Services, University of Dundee (opens in a new tab)
- Building a bridge between organoid research and drug discovery - BMG LABTECH (opens in a new tab)
- Video interview with Elad Katz, 3 March 2025 - SelectScience (opens in a new tab)
- Biotech start-ups at ELRIG Drug Discovery 2024 - Technology Networks (opens in a new tab)
- Drug discovery innovation in Scotland, September 2024 - Drug Discovery World (opens in a new tab)
- Academic Adventures Podcast episode listing - Podimo (opens in a new tab)
- Elad Katz, Honorary Research Fellow - University of Dundee Discovery Portal (opens in a new tab)
This case describes Elad Katz’s own work before Grand Rounds, as Elad’s profile and the public sources above describe it. It is not a Grand Rounds engagement and not a promise of the same result for another company.